Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. Antibodies
  4. Primary Antibodies
  5. All Primary Antibodies
  6. Invitrogen™ CD276 (B7-H3) Recombinant Rat Monoclonal Antibody (M3.2D7) 

Invitrogen™ CD276 (B7-H3) Recombinant Rat Monoclonal Antibody (M3.2D7)

Catalog No. 740074T20UG
Encompass_Preferred
Change view
Click to view available options
Quantity:
20 μL
100 μL
2 product options available for selection
Product selection table with 2 available options. Use arrow keys to navigate and Enter or Space to select.
Catalog No. Quantity
74-007-4T20UG 20 μL
74-007-4T 100 μL
Use arrow keys to navigate between rows. Press Enter or Space to select a product option. 2 options available.
2 options
Catalog No. 74-007-4T20UG Supplier Invitrogen™ Supplier No. 740074T20UG
Add to Cart
Edge
Add to Cart

Description

Rat Recombinant Monoclonal Antibody

Recombinant rat monoclonal antibodies are produced using in vitro expression systems. Recombinant antibodies are produced using specific genes that code for the desired antibodies. These genes are cloned into an expression vector and expressed in vitro. The advantages of recombinant antibodies include: better specificity, lot-to-lot consistency, and broader immunoreactivity to diverse targets due to a larger rabbit immune repertoire. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest.

CD276 is a member of the B7 family of co-stimulatory molecules also known as B7-H3. CD276 is a type I transmembrane protein that induces the proliferation of CD4+ and CD8+ T cells, enhances the generation of cytotoxic T cells and selectively stimulates the production of interferon gamma. Expression of CD276 can be induced on dendritic cells and monocytes by inflammatory cytokines, and is also widely expressed in peripheral tissues including the heart, kidney, testis and colon. In humans, CD276 exists as two isoforms which result from gene duplication and differential splicing. CD276 is reported to have therapeutic potential for the regulation of cell-mediated immune responses to cancer, particularly in conjunction with anti-angiogenic therapy.
TRUSTED_SUSTAINABILITY

Specifications

Antigen CD276 (B7-H3)
Applications Flow Cytometry, Immunohistochemistry (Paraffin), Western Blot
Classification Recombinant Monoclonal
Clone M3.2D7
Concentration 1.0 mg/mL
Conjugate Unconjugated
Formulation PBS with 0.09% sodium azide; pH 7.4
Gene CD276
Gene Accession No. Q5ZPR3, Q8VE98
Gene Alias 4Ig-B7-H3; 6030411F23Rik; AU016588; B7 homolog 3; B7h3; B7-H3; B7RP-2; CD276; CD276 antigen; CD276 molecule; CD276 molecule tv1; costimulatory molecule; PSEC0249; sB7 H3; sB7H3; sCD276; soluble B7 H3; soluble B7H3; soluble CD276; UNQ309/PRO352
Gene Symbols CD276
Host Species Rat
Purification Method Affinity chromatography
Quantity 20 μL
Regulatory Status RUO
Primary or Secondary Primary
Gene ID (Entrez) 102657, 80381
Target Species Human, Mouse
Content And Storage -20°C, Avoid Freeze/Thaw Cycles
Product Type Antibody
Form Liquid
Isotype IgG2a
Show More Show Less
Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.